Ortho Clinical Diagnostics (NASDAQ:OCDX) Now Covered by Analysts at Morgan Stanley

Morgan Stanley initiated coverage on shares of Ortho Clinical Diagnostics (NASDAQ:OCDX) in a report issued on Monday morning, The Fly reports. The brokerage issued an overweight rating and a $24.00 target price on the stock.

Several other analysts also recently weighed in on the stock. Bank of America started coverage on shares of Ortho Clinical Diagnostics in a report on Monday. They issued a buy rating and a $23.00 target price for the company. Citigroup started coverage on shares of Ortho Clinical Diagnostics in a research note on Monday. They issued a buy rating and a $20.00 price target for the company. HC Wainwright started coverage on shares of Ortho Clinical Diagnostics in a research note on Monday. They issued a buy rating and a $27.00 price target for the company. UBS Group started coverage on shares of Ortho Clinical Diagnostics in a research note on Monday. They issued a buy rating and a $23.00 price target for the company. Finally, The Goldman Sachs Group started coverage on shares of Ortho Clinical Diagnostics in a research note on Monday. They issued a buy rating and a $27.00 price target for the company. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $24.00.

OCDX stock opened at $17.11 on Monday. Ortho Clinical Diagnostics has a one year low of $15.14 and a one year high of $18.65.

Ortho Clinical Diagnostics Company Profile

Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business in the United States. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a broad spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases.

Recommended Story: Capital Gains Distribution

The Fly

Analyst Recommendations for Ortho Clinical Diagnostics (NASDAQ:OCDX)

Receive News & Ratings for Ortho Clinical Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ortho Clinical Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit